Abstract 356P
Background
Terminal cancer pain continues to be a significant morbidity. Most of the patients need intervention by pain specialists - and few still remain “difficult to treat”. In India, most of these patients do shift to alternative medicine in desperation, with active ingredients, such as steroids/cannabinoids, and few unclassified anti-tumor substances. After listing and analyzing these the two most frequently observed ones are steroids and cannabinoids wherever patients have satisfactory pain control.
Methods
An interview based study was conducted as a part of QOL Data collection, which included other symptoms (such as fatigue, cachexia, well-being etc.) in the period of 2016-2018. One of key inclusions was - patients with advanced cancer progressed on multiple lines for which there was no standard of care. After data collection, a subset analysis was conducted with reference to pain control and use of alternative medication. For ease of analysis subjects were grouped into 4 categories based on pain control with opioids and concurrent use of cannabinoids. Subjects whose nature of the medication was not known were excluded. All four groups were analyzed for the pain control with help of visual analogy scale (VAS).
Results
The baseline demographic characters in all four groups were well balanced and depicted in Table -1. Overall there were no statistically significant differences in the duration of symptoms, average dose of opioid analgesia, performance status and the stage of disease. Pain relief was better in the cannabis group, when it was used independently or in combination with opioids. No significant additional side effects pertaining to cannabis were reported by the patients. The overall qualities of life, as well as weight gain and nausea control were better in the cannabis group.
Conclusions
We could infer that Bhang [cannabis crude form], is an effective analgesic independently having synergy with opioids. It also improved overall QOL, especially in cachexia, without adverse effects. If scientifically proven with pharmaceutical grade, it will be a significant addition to the symptomatic care of terminally ill cancer patients. Though available in US, India still does not have regulatory approval for medical cannabis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract